Skip to content
Hair Pipeline
← Back to the pipeline

GT20029

A topical PROTAC that destroys the androgen receptor rather than just blocking it.

Phase 2TopicalAndrogen receptor

No public activity in over 18 months

Developed by
Kintor Pharmaceutical
Current phase
Phase 2

Tests whether it works, at what dose, in a few hundred people.

Indications
Androgenetic alopecia
Also known as
GT-20029
Last public activity
November 2024
Record confidence
Medium

How it is meant to work

Where a conventional antiandrogen occupies the receptor, a PROTAC tags it for the cell's own disposal machinery. In principle that gives a longer-lasting effect from less frequent dosing.

Development history

  1. Phase 1Phase 2

    First Phase 2 trial on record: NCT06692465 — To Evaluate the Efficacy and Safety of GT20029 Solution in the Treatment of Androgenetic Alopecia (AGA) in Chinese Adult Males

    ClinicalTrials.gov ↗
  2. Phase 1

    First Phase 1 trial on record: NCT06468579 — To Evaluate the Safety, Tolerability and PK of GT20029 Gel and Solution in Healthy Subjects

    ClinicalTrials.gov ↗

Registered trials

Pulled automatically from ClinicalTrials.gov. Matching is by name and development code, so occasional gaps are possible — tell us if you spot one.

  • NCT06692465Phase 2COMPLETED

    To Evaluate the Efficacy and Safety of GT20029 Solution in the Treatment of Androgenetic Alopecia (AGA) in Chinese Adult Males

    Suzhou Kintor Pharmaceutical Inc, · n=180 · April 2023

  • NCT05428449Phase 1COMPLETED

    Study in Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of GT20029

    Suzhou Kintor Pharmaceutical Inc, · n=123 · February 2022

  • NCT06468579Phase 1COMPLETED

    To Evaluate the Safety, Tolerability and PK of GT20029 Gel and Solution in Healthy Subjects

    Suzhou Kintor Pharmaceutical Inc, · n=92 · July 2021

Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first.

Sources